The COVID-19 Payer Pulse Survey

Posted by Ed Schoonveld on Mon, Apr 27, 2020

Many of our clients have been asking us about the impact of COVID-19 on coverage approvals and the management of prescription drugs. We used our rapid response PayerLIVE survey instrument to get some reactions from U.S., EU and Canadian payers with respect to the impact of COVID-19 on their functioning, pharma industry relationships and expectations for the near future.


>
Read More

Rising unemployment and its impact on pharma's top and bottom line

Posted by Ricky Yuen on Mon, Apr 20, 2020

Kyle Harpole and Nishank Kanungo co-wrote this blog post with Ricky Yuen.

Access COVID-19 resources

Unemployment claims are at 22 million and climbing due to the COVID-19 pandemic, and like the great recession of 2008, rising unemployment means that patients will shift from employer-sponsored coverage to ACA health exchange plans or Medicaid, or become uninsured. In addition, the financial constraints on payers and providers due to this event are unprecedented, all with the backdrop of upcoming elections and other reforms already being planned. Given this seismic impact on the healthcare landscape, U.S. market access organizations will need to start thinking about the lasting impact of COVID-19 on market access analytics, contracting and gross-to-net (GTN).


>
Read More

What could be in store for the value and access landscape?

Posted by Richard Secker-Johnson on Tue, Apr 07, 2020

While the immediate impact of coronavirus on the pharmaceutical industry is evident, one area of uncertainty is how the virus will alter the landscape for the pricing and access of medicines in the longer term. Much of this impact will likely be linked to the macroeconomic effects of coronavirus, where we can speculate that changes in the size of economies as well as reprioritization of healthcare spending may alter payers’ ability and willingness to pay for medicines overall, and also for certain diseases and classes of medicine. However, another significant factor could be the impact of the virus on the value and access policy landscape. While there’s still uncertainty around how these policy changes could develop, we can look to some of the immediate global reactions to coronavirus that may serve as leading indicators of potential mid- to longer-term policy change.


>
Read More

COVID-19: Now and Beyond

Posted by Ed Schoonveld on Tue, Mar 17, 2020

How does the COVID-19 pandemic impact the pharmaceutical industry and the drug pricing debate? In the short term, it may have caused a temporary break in the drug pricing media deluge, but it likely will create questions about new vaccine’s affordability and its ability to reach a broad patient population. As the disease’s spread continues to dominate the world stage, many pharmaceutical companies and university laboratories are working hard to identify treatment and vaccination options for COVID-19.


>
Read More